CHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AML
The goal of this phase 2 trial is to test the safety and efficacy of CHG Combined With Venetoclax in treating patients with newly diagnosed AML.
Acute Myeloid Leukemia
DRUG: CHG Combined With Venetoclax and Azacytidine
Overall Response Rate (ORR), ORR was defined as the proportion of patients who achieved CR or PR as their best response, 1 year
Overall Survival (OS), OS was defined as time from diagnosis to death from any cause or the last follow-up, through study completion, an average of 3 years|Progression Free Survival (PFS), For patients in morphologic remission, documented relapse was considered progression. Relapse following complete remission(CR) is defined as reappearance of leukemic blasts in the peripheral blood or the finding of more than 5% blasts in the BM, not attributable to another cause (eg, BM regeneration after consolidation therapy) or extramedullary relapse., 2 years
The investigators will evaluate response rate of CHG regimen Combined With Venetoclax in newly diagnosed acute myeloid leukemia. After induction therapy, patients will be given standardized treatment according to risk stratification according to NCCN guidelines. Progression free survival (PFS), Overall survival (OS), and Toxicity will be counted.